These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35288476)

  • 1. Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Bridel C; Killestein J; Teunissen C
    Neurology; 2022 Mar; 98(11):471. PubMed ID: 35288476
    [No Abstract]   [Full Text] [Related]  

  • 2. Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Kropshofer H; Häring DA; Kappos L; Leppert D; Kuhle J
    Neurology; 2022 Mar; 98(11):470-471. PubMed ID: 35288475
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
    Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of neurofilament light chain in natalizumab therapy for different phases of multiple sclerosis: A systematic review and meta-analysis.
    Liu N; Sun M; Zhang W; Sun J; Gong P; Wang H; Wang M
    J Clin Neurosci; 2022 Jul; 101():198-203. PubMed ID: 35617924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
    Almeida KJ; Barreto-Soares RV; Campos-Sousa RN; Campos-Sousa MG; Bor-Seng-Shu E
    Mult Scler; 2018 Jun; 24(7):1002-1004. PubMed ID: 29649930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebral abscess in a multiple sclerosis patient during treatment with natalizumab.
    Durmus B; Van Goethem J; Vercruyssen A; De la Meilleure G; Jadoul C; Willekens B
    Acta Neurol Belg; 2020 Feb; 120(1):215-217. PubMed ID: 30953297
    [No Abstract]   [Full Text] [Related]  

  • 7. Natalizumab treatment for multiple sclerosis inducing a toxic acute myocardial damage. Is there any relationship?
    Fama' F; Dattola V; Cicciu' M; Buccafusca M; Russo M; Lo Presti D; Dattilo G; Di Bella G
    Int J Cardiol; 2016 Mar; 206():127-8. PubMed ID: 26788687
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
    Fissolo N; Pignolet B; Rio J; Vermersch P; Ruet A; deSèze J; Labauge P; Vukusic S; Papeix C; Martinez-Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Bourre B; Defer G; Montalban X; Brassat D; Comabella M
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33903203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma.
    Kaye AE; Hawkes ED; Gout II; El-Amir AN; Neffendorf JE
    Mult Scler Relat Disord; 2018 Nov; 26():74-76. PubMed ID: 30237107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible hyporegenerative anemia during natalizumab treatment.
    Monteleone F; Buccisano F; Boffa L; Buttari F; Di Veroli A; Borriello G; Rossi S; Centonze D
    Mult Scler; 2015 Feb; 21(2):257-8. PubMed ID: 25186208
    [No Abstract]   [Full Text] [Related]  

  • 11. Recurrent skin infections associated with natalizumab treatment.
    Oliveira DS; Castro AR; Ruano L
    Neurol Sci; 2023 Mar; 44(3):1093-1095. PubMed ID: 36331655
    [No Abstract]   [Full Text] [Related]  

  • 12. Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
    Foley RW; Tagg NT; Schindler MK; Fenton KM; Reich DS; Cortese I; Mowry EM
    Mult Scler; 2017 Sep; 23(10):1424-1427. PubMed ID: 28639536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
    Yamout BI; Abou Zeid N; Taha AJ; Zeineddine MM; Khoury SJ
    Mult Scler Relat Disord; 2016 Sep; 9():122-4. PubMed ID: 27645358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy.
    Guilloton L; Pegat A; Defrance J; Quesnel L; Barral G; Drouet A
    J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):301-302. PubMed ID: 28403930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe thrombocytopenia during Natalizumab therapy: A case report.
    Rini AM; Clerici VT; Rinaldi E; Modesto M; Pastore D; Confalonieri PA; Passarella B
    J Neurol Sci; 2020 Feb; 409():116587. PubMed ID: 31805430
    [No Abstract]   [Full Text] [Related]  

  • 16. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
    Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
    Johnsson M; Farman HH; Blennow K; Zetterberg H; Malmeström C; Axelsson M; Lycke J
    Mult Scler; 2022 Nov; 28(13):2070-2080. PubMed ID: 35856574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
    Yap SM; McGuigan C
    Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039
    [No Abstract]   [Full Text] [Related]  

  • 19. Concurrent management of multiple sclerosis and natalizumab-induced hepatitis with ofatumumab: a case report.
    Haggiag S; Giannelli V; Prosperini L; Cruciani A; Baiocchini A; Ruggieri S; Pellicelli A; Gasperini C; Tortorella C
    Neurol Sci; 2024 Oct; 45(10):5087-5089. PubMed ID: 38861049
    [No Abstract]   [Full Text] [Related]  

  • 20. Measurement of anti-natalizumab antibodies by homogeneous mobility shift assay.
    Keating PE; Duncan R; Spellerberg M; O'Donnell J; Hock BD
    Pathology; 2020 Apr; 52(3):373-374. PubMed ID: 32113675
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.